Biogen Inc. (BIIB) reported results in line with expectations in FY2026 on revenue of $54.7B versus the $55.7B estimate (+14.3% YoY) and EPS of $3.55. Below is the full Biogen Inc. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Biogen Inc. (BIIB) Earnings Analysis — key stats
Next earnings date
Jan 30, 2025
Latest reported quarter
FY2026
Earnings verdict
In line
Revenue
$54.7B (vs $55.7B est · -1.8% surprise · +14.3% YoY)
EPS
$3.55 (vs $3.57 est · -0.6% surprise · +38.4% YoY)
Share price
$82.04 (-2.8%)
Market cap
$1.26T
What you'll find
Next Biogen Inc. (BIIB) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Biogen Inc. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Biogen Inc. (BIIB)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Biogen Inc.'s next earnings date?
Biogen Inc.'s (BIIB) next scheduled earnings date is Jan 30, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Biogen Inc. (BIIB) beat or miss earnings?
In FY2026, Biogen Inc. (BIIB) posted in-line results — revenue of $54.7B versus the $55.7B estimate (-1.8% surprise) and EPS of $3.55 versus $3.57 expected (-0.6% surprise). Magnisto decodes every Biogen Inc. (BIIB) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Biogen Inc. (BIIB) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Biogen Inc. (BIIB), anchored to the current $82.04 share price, so you can weigh the bull, base and bear cases for Biogen Inc. side by side.
Is Biogen Inc. (BIIB) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Biogen Inc. fits your own thesis and risk profile. This is research, not investment advice.